Study backs tapering of baricitinib in RA patients

Baricitinib doses can be tapered without risk of relapse in most RA patients who achieve remission or low disease activity with the targeted synthetic DMARD, a study has shown. The first randomised controlled trial of tapering of the selective Janus kinase 1 and 2 inhibitor showed that it was feasible to move to a reduced ...

Already a member?

Login to keep reading.

© 2021 the limbic